Rapamycin and Its Binding to Cancer Receptors
Author Information
Author(s): Ganesh Sanjeev K., Devi C. Subathra
Primary Institution: Vellore Institute of Technology, Vellore, Tamil Nadu, India
Hypothesis
Rapamycin, beyond its established role as an mTOR inhibitor, may interact with other oncogenic receptors involved in cancer progression, thereby expanding its potential therapeutic applications.
Conclusion
Rapamycin shows significant binding affinity to multiple cancer-related receptors, enhancing its potential effectiveness in treating lung cancer.
Supporting Evidence
- Rapamycin showed a potent impact with LC50 value of 32.99 against A549 lung cancer cell line.
- Binding affinity of rapamycin to EGFR was greater than that of positive control drugs.
- Rapamycin treatment induced significant morphological alterations in cancer cell lines.
Takeaway
Rapamycin is a medicine that can help fight cancer by sticking to different parts of cancer cells, not just the usual one.
Methodology
The study involved molecular docking and simulations to identify rapamycin's binding to various cancer receptors.
Potential Biases
Potential off-target effects on non-cancerous cells expressing the same receptors.
Limitations
The study's findings are based on in-silico analysis, which may not fully replicate in vivo conditions.
Participant Demographics
The study focused on A549 lung cancer cells.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website